Light Exposure to Improve Cognition, Sleep, and Metabolism
Start: April 1, 2019
End: August 31, 2023
Enrollment: 30
What Is This Study About?
This study will evaluate the long-term effects of a treatment using light on cognition, sleep, and metabolism in people with mild cognitive impairment (MCI), mild Alzheimer's disease, or a related dementia. Participants will be randomly assigned to receive either a tailored light intervention or a placebo treatment at home for six months. The intervention will provide daily stimulation with bluish-white (experimental) or yellow-white (control) light sources that are tuned to the sensitivity of the circadian system, which controls the human sleep-wake cycle. Researchers will measure if the intervention can reduce sleep disturbances, inflammation, insulin sensitivity, and improve glucose metabolism and cognition.
Do I Qualify To Participate in This Study?
Minimum Age: 55 Years
Maximum Age: N/A
Must have:
- MCI, mild Alzheimer's disease, or a related dementia with:
- MMSE score of >19 or Clinical Dementia Rating of 0.5 or 1
- Sleep problems, including waking often or having trouble staying asleep through the night
- Live at home
Must NOT have:
- Blindness
- Insulin-dependent diabetes
- Macular degeneration
- Severe sleep apnea
If I Qualify, Who Do I Contact?
Contact study personnel listed either under the general study contact or the location nearest you.
Need Help?
Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.
Where Is This Study Located?
| New Jersey | |
|---|---|
|
Rutgers University
New Brunswick, NJ 08854
Recruiting
Christoph Buettner, MD |
|
| New York | |
|
Icahn School of Medicine at Mount Sinai
New York, NY 10029
Recruiting
Christoph Buettner, MD, PhD |
|
Who Sponsors This Study?
Lead: Rensselaer Polytechnic Institute
Collaborator Sponsor
- Icahn School of Medicine at Mount Sinai
Source: ClinicalTrials.gov ID: NCT03933696